(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 December 2020 (17.12.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/249792 A1

(51) International Patent Classification:
A61P 25/00 (2006.01) *A61K 31/437* (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:
PCT/EP2020/066392

(22) International Filing Date:
12 June 2020 (12.06.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/861,656	14 June 2019 (14.06.2019)	US
350/2020	03 June 2020 (03.06.2020)	PK
P20200101623	09 June 2020 (09.06.2020)	AR

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **HISCOX, Afton**; 48 Dewson St, Apt 1, Toronto, ON, M6H 1G7 (CA). **SOYODE-JOHNSON, Akinola**; 3210 Merryfield Row, San Diego, California 92121 (US). **STENNE, Brice**; 3210 Merryfield Row, San Diego, California 92121 (US). **CHROVIAN, Christa**; 3210 Merryfield Row, San Diego, California 92121 (US). **GELIN, Christine**; 3210 Merryfield Row, San Diego, California 92121 (US). **SAMANT, Andrew**; 3210 Merryfield Row, San Diego, California 92121 (US). **LETAVIC, Michael A.**; 3210 Merryfield Row, San Diego, California 92121 (US). **DVORAK, Curt**; 3210 Merryfield Row, San Diego, California 92121 (US).

(74) Agent: **DUFFIELD, Stephen** et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

(57) Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

WO 2020/249792 A1